Use of lacosamide in children: experience of a tertiary medical care center in Brazil
Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 y...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academia Brasileira de Neurologia (ABNEURO)
2022-11-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1758366 |
| _version_ | 1797975383490953216 |
|---|---|
| author | Tayla Taynan Romão Abraão Iuri Medeiros Angelim Henrique Jannuzzelli Pires do Prado Fernanda Veiga de Goes Maria Elisa Paiva Pires Rosiane da Silva Fontana Lais de Carvalho Pires Alexandre Ribeiro Fernandes Isabella D'Andrea-Meira |
| author_facet | Tayla Taynan Romão Abraão Iuri Medeiros Angelim Henrique Jannuzzelli Pires do Prado Fernanda Veiga de Goes Maria Elisa Paiva Pires Rosiane da Silva Fontana Lais de Carvalho Pires Alexandre Ribeiro Fernandes Isabella D'Andrea-Meira |
| author_sort | Tayla Taynan Romão |
| collection | DOAJ |
| description | Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age.
Objective To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment.
Methods A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM.
Results After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers.
Conclusions Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures. |
| first_indexed | 2024-04-11T04:34:42Z |
| format | Article |
| id | doaj.art-626c334377fa4fcabb42e4e643025fc7 |
| institution | Directory Open Access Journal |
| issn | 0004-282X 1678-4227 |
| language | English |
| last_indexed | 2024-04-11T04:34:42Z |
| publishDate | 2022-11-01 |
| publisher | Academia Brasileira de Neurologia (ABNEURO) |
| record_format | Article |
| series | Arquivos de Neuro-Psiquiatria |
| spelling | doaj.art-626c334377fa4fcabb42e4e643025fc72022-12-28T23:41:54ZengAcademia Brasileira de Neurologia (ABNEURO)Arquivos de Neuro-Psiquiatria0004-282X1678-42272022-11-0180111090109610.1055/s-0042-1758366Use of lacosamide in children: experience of a tertiary medical care center in BrazilTayla Taynan Romão0Abraão Iuri Medeiros Angelim1Henrique Jannuzzelli Pires do Prado2Fernanda Veiga de Goes3Maria Elisa Paiva Pires4Rosiane da Silva Fontana5Lais de Carvalho Pires6Alexandre Ribeiro Fernandes7Isabella D'Andrea-Meira8Universidade Federal Fluminense, Faculdade de Medicina, Departamento de Neurologia, Niterói RJ, Brazil.Instituto Estadual do Cérebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil.Instituto Estadual do Cérebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil.Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Departamento de Neurologia, Rio de Janeiro RJ, Brazil.Instituto Estadual do Cérebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil.Instituto Estadual do Cérebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil.Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Departamento de Neurologia, Rio de Janeiro RJ, Brazil.Universidade Federal Fluminense, Faculdade de Medicina, Departamento de Neurologia, Niterói RJ, Brazil.Universidade Federal Fluminense, Faculdade de Medicina, Departamento de Neurologia, Niterói RJ, Brazil.Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1758366epilepsylacosamidechilddrug resistant epilepsypediatric assistants |
| spellingShingle | Tayla Taynan Romão Abraão Iuri Medeiros Angelim Henrique Jannuzzelli Pires do Prado Fernanda Veiga de Goes Maria Elisa Paiva Pires Rosiane da Silva Fontana Lais de Carvalho Pires Alexandre Ribeiro Fernandes Isabella D'Andrea-Meira Use of lacosamide in children: experience of a tertiary medical care center in Brazil Arquivos de Neuro-Psiquiatria epilepsy lacosamide child drug resistant epilepsy pediatric assistants |
| title | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
| title_full | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
| title_fullStr | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
| title_full_unstemmed | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
| title_short | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
| title_sort | use of lacosamide in children experience of a tertiary medical care center in brazil |
| topic | epilepsy lacosamide child drug resistant epilepsy pediatric assistants |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1758366 |
| work_keys_str_mv | AT taylataynanromao useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT abraaoiurimedeirosangelim useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT henriquejannuzzellipiresdoprado useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT fernandaveigadegoes useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT mariaelisapaivapires useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT rosianedasilvafontana useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT laisdecarvalhopires useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT alexandreribeirofernandes useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT isabelladandreameira useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil |